AOD 9604 peptide vs tesamorelin compared: how each works, typical dosing, cost, side effects, and which research goals each compound fits best.
AOD 9604 and tesamorelin are both peptides studied for fat loss, but they are not interchangeable. AOD 9604 is a synthetic fragment of human growth hormone that mimics its fat-burning piece without raising IGF-1, while tesamorelin is an FDA-approved GHRH analog that prompts the pituitary to release growth hormone. The biggest practical difference is regulatory: tesamorelin is a prescription drug with a defined indication, and AOD 9604 is sold only as a research chemical that is not approved for human use in the United States.
What Is AOD 9604?
AOD 9604 is a 16-amino-acid peptide modeled on the C-terminal region of human growth hormone, often written as hGH 177–191. Scientists designed it to isolate the lipolytic, or fat-releasing, activity of GH while stripping out the parts tied to IGF-1 production, blood sugar changes, and tissue growth.
That design is why AOD 9604 does not raise IGF-1 or shut down natural growth hormone output. Most discussion around peptide aod 9604 benefits centers on fat metabolism without the water retention, joint aches, or insulin resistance that can come with full growth hormone.
The human evidence is thin and mixed. A Phase IIb trial in adults with obesity did not hit its primary weight-loss endpoint versus placebo, and no US regulator has approved AOD 9604 for any human condition.
What Is Tesamorelin?
Tesamorelin is a 44-amino-acid growth hormone–releasing hormone (GHRH) analog sold under the brand names Egrifta and Egrifta SV. It binds GHRH receptors in the pituitary and prompts the body to release its own growth hormone in pulses, which in turn raises IGF-1.
The FDA approved tesamorelin to reduce excess visceral abdominal fat in adults living with HIV-associated lipodystrophy. That approval rests on randomized trials showing measurable reductions in visceral adipose tissue, not just changes on a scale.
Because tesamorelin acts upstream at the pituitary, its effects reach further than fat tissue. It shifts IGF-1 levels, can affect glucose handling, and may cause fluid retention, which is why it is used under medical supervision.
AOD 9604 vs Tesamorelin: Side-by-Side
The table below summarizes how these two peptides differ in mechanism, approval status, dosing, and side effects.
| Feature | AOD 9604 | Tesamorelin |
|---|---|---|
| Peptide class | hGH fragment (amino acids 177–191) | GHRH analog (44 amino acids) |
| How it works | Mimics the fat-metabolizing portion of growth hormone | Stimulates pituitary GH release, which raises IGF-1 |
| Effect on IGF-1 | Little to none | Increases IGF-1 |
| FDA status | Not approved for human use | Approved (Egrifta / Egrifta SV) for HIV-associated visceral fat |
| Human evidence | Mixed; obesity trial missed its primary endpoint | Randomized trials show visceral fat reduction |
| Typical dose | 250–600 mcg per day | 1.4–2 mg once daily |
| Common side effects | Injection-site irritation, generally mild | Injection-site reactions, myalgia, arthralgia, edema |
| Access | Research chemical suppliers | Prescription only |
Tesamorelin is the only one of the two with FDA approval for a human indication, and that approval is narrow: HIV-associated visceral fat accumulation. AOD 9604 remains a laboratory research peptide.
Dosing and Timing Differences
Both compounds are given by subcutaneous injection, usually into the abdomen, but the schedules and amounts are very different.
| Detail | AOD 9604 | Tesamorelin |
|---|---|---|
| Typical research dose | 250–600 mcg per day, often split into two injections | 1.4 mg (Egrifta SV) or 2 mg once daily |
| Timing | Empty stomach, often morning or pre-workout | Bedtime, to align with natural GH pulses |
| Half-life | Roughly 15–30 minutes | Roughly 26–38 minutes |
People searching for when to take aod 9604 peptide usually find the same guidance: fasted, because meals — especially carbohydrates and fats — can blunt the fat-release response. Tesamorelin is dosed at night for a different reason: it mimics the body's largest natural growth hormone pulse, which occurs during deep sleep.
Side Effects, Safety, and Legal Status
- AOD 9604: Reported side effects are usually mild and include injection-site irritation. Long-term human safety data do not exist.
- Tesamorelin: Common effects include injection-site reactions, muscle pain, joint pain, and peripheral edema. It raises IGF-1 and can affect blood sugar.
- Contraindications: Tesamorelin is not for people with active cancer, pituitary gland disruption, or pregnancy. Prescribers monitor IGF-1 and glucose.
- Legal status: AOD 9604 is not FDA-approved for human use and is sold as "research use only." Tesamorelin requires a prescription.
AOD 9604 has not been established as safe or effective for human use in the United States.
Anyone considering either peptide should talk with a licensed healthcare professional, especially if they have diabetes, a history of cancer, or a hormone-sensitive condition.
Because AOD 9604 is not a drug, people who look to buy aod-9604 peptide are typically buying unregulated powder or pre-mixed vials from research suppliers. Purity and sterility vary widely, and a certificate of analysis is not a guarantee of safety. Tesamorelin, by contrast, is dispensed through pharmacies with a prescription.
Which Peptide Fits the Question You're Asking?
If the goal is a regulated, evidence-backed treatment for visceral fat in a specific clinical population, tesamorelin is the only one of the two with that standing. If the goal is a non-hormonal compound that targets fat metabolism without touching IGF-1, AOD 9604 is the closer tool, but its human data are weak.
It also helps to consider nearby options. A comparison like aod 9604 vs mots-c comes up because MOTS-c is a mitochondrial-derived peptide studied for metabolic function, a different pathway entirely from either AOD 9604 or tesamorelin.
Some people ask about aod 9604 with tesamorelin for stacking, reasoning that a GHRH analog plus a lipolytic fragment could cover two mechanisms at once. No controlled human trials have tested that combination, so the risk of overlapping side effects and unmonitored IGF-1 changes is unknown.
The bottom line: tesamorelin is a prescription drug with FDA-approved evidence for visceral fat in one defined population, and AOD 9604 is an unapproved research peptide with mixed human results and no established safety profile.
Frequently Asked Questions
Is AOD 9604 or tesamorelin better for losing belly fat?
Tesamorelin has the stronger evidence for visceral belly fat. It is FDA-approved to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy, based on randomized trials, while AOD 9604 failed to beat placebo for weight loss in a Phase IIb obesity trial. Neither peptide is a general-purpose weight loss drug.
Is AOD 9604 FDA-approved?
No. AOD 9604 is not approved by the FDA for any human use and is sold only as a research chemical labeled "not for human consumption." Tesamorelin, by contrast, is FDA-approved under the brand names Egrifta and Egrifta SV for a specific form of visceral fat accumulation.
Can you stack AOD 9604 with tesamorelin?
Some people combine them because they act on different pathways: tesamorelin stimulates pituitary growth hormone release, while AOD 9604 mimics a fat-metabolizing growth hormone fragment. No controlled human studies have tested the combination, and stacking raises the chance of additive side effects, including unmonitored IGF-1 increases from tesamorelin. Talk with a healthcare professional before combining any peptides.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.